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The CpG island methylator phenotype (CIMPþ) in colorectal cancer (CRC) is defined as concomitant and frequent
hypermethylation of CpG islands within gene promoter regions. We previously demonstrated that CIMPþ was associated with
elevated concentrations of folate intermediates in tumour tissues. In the present study, we investigated whether CIMPþ was
associated with a specific mRNA expression pattern for folate- and nucleotide-metabolising enzymes. An exploratory study was
conducted on 114 CRC samples from Australia. mRNA levels for 17 genes involved in folate and nucleotide metabolism were
measured by real-time RT-PCR. CIMPþ was determined by real-time methylation-specific PCR and compared to mRNA
expression. Candidate genes showing association with CIMPþ were further investigated in a replication cohort of 150 CRC samples
from Japan. In the exploratory study, low expression of g-glutamyl hydrolase (GGH) was strongly associated with CIMPþ and
CIMPþ-related clinicopathological and molecular features. Trends for inverse association between GGH expression and the
concentration of folate intermediates were also observed. Analysis of the replication cohort confirmed that GGH expression was
significantly lower in CIMPþ CRC. Promoter hypermethylation of GGH was observed in only 5.6% (1 out of 18) CIMPþ tumours
and could not account for the low expression level of this gene. CIMPþ CRC is associated with low expression of GGH, suggesting
involvement of the folate pathway in the development and/or progression of this phenotype. Further studies of folate metabolism in
CIMPþ CRC may help to elucidate the aetiology of these tumours and to predict their response to anti-folates and 5-fluorouracil/
leucovorin.
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Cancer is a disease with genetic and epigenetic abnormalities.
Aberrant CpG island methylation is a common epigenetic
alteration in a variety of malignancies (Jones, 2002). De novo
methylation of CpG islands in promoter regions is believed to
contribute to tumorigenesis by causing transcriptional silencing of
tumour suppressor genes. Colorectal cancer (CRC) is one of the
malignancies in which epigenetic changes have been extensively
analysed. Research on clinical samples has shown that a subgroup
of CRC shows concurrent hypermethylation of a large number of
CpG islands. These have been termed CIMPþ, for CpG island
methylator phenotype (Toyota et al, 1999). CIMPþ tumours occur
more frequently in the proximal colon of older patients and are
associated with the microsatellite instability (MSIþ) phenotype,
tumour-infiltrating lymphocytes (TILs) and mutations in the
BRAF oncogene (Hawkins et al, 2002; van Rijnsoever et al, 2002;
Samowitz et al, 2005). Quantitative DNA methylation analysis
using real-time techniques indicates that approximately 17% of
CRC are CIMPþ (Ogino et al, 2006; Weisenberger et al, 2006;
Iacopetta et al, 2007). A panel of five CpG island markers was
recently proposed to standardise the definition of CIMPþ status
(Weisenberger et al, 2006).
Although the existence of a CIMPþ CRC subgroup is evident,
the aetiology of this phenotype is not well understood. We
previously reported that CIMPþ was associated with elevated
concentrations of the folate intermediates CH2FH4 and FH4 in CRC
tissues (Kawakami et al, 2003). This suggests that folate
metabolism may be an important factor in determining the DNA
methylation status of primary CRC. Folate plays a major role in
cellular homeostasis as a donor of one-carbon units for DNA
methylation, protein methylation and nucleotide synthesis. In-
creased dietary folate intake and serum levels of folate show
correlations with increased global DNA methylation levels in
epidemiological studies (Pufulete et al, 2005b), animal models
(Sohn et al, 2003) and clinical intervention studies (Pufulete et al,
2005a). Associations between dietary folate intake (van Engeland
et al, 2003) or genetic variants in folate-metabolising enzymes (Paz
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set al, 2002) and CpG island hypermethylation in CRC have also
been reported, although other workers have found less evidence
for this (Curtin et al, 2007; Slattery et al, 2007). These observations
suggest that folate metabolism, at least in part, can influence CpG
island methylation and may therefore be involved in the
development of CIMPþ CRC, although firm evidence for this is
still lacking.
Two key metabolic pathways for methyl donor/one-carbon
transfer reactions are the synthesis of folate and nucleotides. In the
present study, we hypothesised that a specific expression pattern
for folate- and nucleotide-metabolising enzymes occurs in CIMPþ
CRC. Our rationale was that a distinctive gene expression signature
may be associated with the aberrant methyl group metabolism of
CIMPþ tumours, as evidenced by the frequent CpG island
hypermethylation. To test this hypothesis, the mRNA expression
levels of 17 genes with important roles in folate and nucleotide
metabolism were measured by real-time RT-PCR in two series of
primary CRC in which the CIMPþ status was determined by
methylation-specific real-time PCR.
MATERIALS AND METHODS
Samples
For exploratory analysis of gene expression levels, tumour samples
from a consecutive series of 114 CRC patients undergoing elective
surgery at the Colorectal Unit of the Royal Adelaide Hospital in
Australia were used. These samples were snap-frozen in liquid
nitrogen within 20–40min of resection and stored at  701C. DNA
was extracted using a QIAamp DNA mini kit (Qiagen, Hilden,
Germany), according to the manufacturer’s protocol. RNA was
obtained from the corresponding formalin-fixed and paraffin-
embedded (FFPE) tissues. FFPE tissue blocks were reviewed for
quality and tumour content, and 5-mm-thick sections were
obtained. Sections were mounted on uncoated glass slides,
deparaffinised in xylene, hydrated and stained with nuclear fast
red (American MasterTech Scientific Inc., Lodi, CA, USA). Tumour
cells were isolated by laser capture microdissection (PALM
Microsystem; Leica, Wetzlar, Germany), according to the standard
procedures (Bonner et al, 1997). RNA isolation after dissection was
performed according to a proprietary procedure (Response
Genetics Inc., US patent no. 6248535). We have previously
measured the concentrations of the folate intermediates CH2FH4
and FH4 (Kawakami et al, 2003) and analysed for BRAF V600E
mutation (Iacopetta et al, 2006) in this tumour series. Approval of
this project was obtained from the IMVS Human Research Ethics
Committee.
For the validation tumour set, 150 primary CRC samples from
patients undergoing surgical treatment at Kanazawa University
Hospital in Japan were used. Tumour was dissected manually from
FFPE archival tissue sections of 10mm thickness. After depar-
affinisation using xylene and ethanol, genomic DNA was isolated
using a QIAamp DNA mini kit. RNA was obtained from the
manually dissected FFPE samples using the same method as for the
Australian CRC series. Approval of this project was obtained from
the Ethics Committee of Kanazawa University School of Medicine.
Real-time RT-PCR and immunohistochemistry
Complementary DNA was prepared as described previously (Lord
et al, 2000). Quantification of the genes of interest (Table 1) and an
internal reference gene (ACTB) was conducted using a fluores-
cence-based real-time detection method (ABI PRISM 7700
Sequence Detection System (TaqMan); Perkin-Elmer Applied
Biosystems, Foster City, CA, USA), as previously described
(Gibson et al, 1996; Dziadziuszko et al, 2006). Gene expression
values were expressed as ratios (differences between Ct values)
between the gene of interest and an internal reference gene
(ACTB). Primer and probe sequences used in this study are listed
in Supplementary Table 1.
For the validation study with Japanese CRC samples, different
primer sets for ECGF1, g-glutamyl hydrolase (GGH), RRM2 and
ACTB (Supplementary Table 1) were used with SYBR Premix Ex
Taq (TaKaRa Bio, Otsu, Japan) and following the protocol
provided by the manufacturer using ABI PRISM 7700 Sequence
Detection System. The quantity of mRNA was expressed as the
ratio of the expression level between each test mRNA and ACTB
mRNA.
Protein expression of GGH in tumour tissues was examined by
immunohistochemistry for selected samples from the Japanese
CRC cohort. The avidin–biotin–peroxidase complex method with
chicken polyclonal antibody (IgY) to human GGH (diluted 1:100;
GenWay Biotech, San Diego, CA, USA) and biotinylated rabbit
anti-chicken IgY (diluted 1:200; Open Biosystems, Huntsville, AL,
USA) was used following microwave antigen retrieval of paraffin
sections, as described previously (Ougolkov et al, 2002).
Methylation analysis
Promoter methylation was evaluated for the CIMP panel of
markers comprising CACNA1G, IGF2, NEUROG1, RUNX3 and
SOCS1, where PMR (percentage methylated reference) values were
derived using the ALU normalisation control reaction (Weisen-
berger et al, 2006). Simultaneous hypermethylation (PMR X10) of
3 or more of these 5 markers was considered to represent CIMPþ.
Promoter hypermethylation of GGH was analysed as previously
described (Cheng et al, 2006). Sperm DNA and fully methylated
DNA by SssI methylase (NewEngland Biolabs, Ipswich, MA, USA)
were used as unmethylated and methylated control samples,
respectively.
Statistical analysis
Because mRNA expression levels did not show normal distribu-
tion, the results were expressed as median values (25th to 75th
percentiles) in tables or boxplots. Non-parametric models were
used for univariate analyses. The Mann–Whitney U-test was used
to compare mRNA expression levels between two categorical
Table 1 Folate- and nucleotide-metabolising genes analysed in this study
Gene
symbol Gene name
GenBank
accession no.
CDA cytidine deaminase NM_001785
DCK deoxycytidine kinase XM_003471
DCTD dCMP deaminase NM_001921
DHFR dihydrofolate reductase NM_000791
DPYD dihydropyrimidine dehydrogenase NM_000110
DUT dUTP pyrophosphatase/deoxyuridine triphosphate
nucleotidohydrolase
U90223
ECGF1 endothelial cell growth factor 1 (platelet-derived)/
thymidine phosphorylase
M63193
FOLR1 folate receptor 1/folate receptor alpha NM_016730
FPGS folylpolyglutamate synthetase M98045
GGH gamma-glutamyl hydrolase NM_003878
MTHFD1 methylene tetrahydrofolate dehydrogenase 1 NM_005956
MTHFR methylene tetrahydrofolate reductase NM_005957
RFC1 reduced folate carrier 1 NM_003056
RRM1 ribonucleotide reductase M1 subunit X59543
RRM2 ribonucleotide reductase M2 subunit NM_001034
TYMS thymidylate synthase NM_001071
UMPS uridine monophosphate synthetase/orotate
phosphoribosyl transferase
XM_050552
Gene symbol is based on the HUGO Gene Nomenclature Committee (http://
www.genenames.org/index.html).
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svariables. Correlations between mRNA expression and the
concentration of folate intermediates were analysed by Spearman’s
rank test. A multivariate stepwise logistic regression approach was
used to select genes whose mRNA expression was significantly
related to CIMP status. All P-values shown are two tailed, with
Po0.05 taken as significant.
RESULTS
Associations between mRNA expression levels for folate-
and nucleotide-metabolising enzymes and CIMPþ or
CIMPþ-related features
RT-PCR assays were conducted for 17 genes in 114 colorectal
tumour samples from Australia. The assays were performed in
triplicate for RT samples and in a single assay for non-RT controls,
resulting in 1938 mRNA measurements by 7752 assays. The non-
RT control reaction was positive in 31 measurements and the
coefficient of variance was high among triplicate assays in four
measurements. These were deemed as ‘no result’. In all, 1903 out of
1938 (98.2%) real-time RT-PCR measurements were successful
using RNA derived from laser capture microdissected FFPE
tumour tissues. CIMPþ was found in 18 out of 114 (15.8%)
CRC samples.
Cluster analysis did not reveal a distinctive mRNA expression
profile associated with CIMPþ (data not shown). In univariate
analysis (Mann–Whitney U-test), GGH expression was signifi-
cantly lower in CIMPþ than CIMP  CRC, whereas the expression
of DCK, DPYD, ECGF1, MTHFR and RRM2 was all higher in
CIMPþ (Table 2). Multivariate analysis using a logistic regression
model showed that GGH expression (odds ratio 0.70, 95% CI:
0.51–0.95, P¼0.023) and RRM2 expression (odds ratio 1.25, 95%
CI: 1.04–1.49, P¼0.015) were associated with CIMPþ (P¼0.008).
Univariate analysis (Mann–Whitney U-test) showed that ECGF1
and GGH expressions were strongly associated with the CIMPþ
features of proximal tumour site, TILs and BRAF mutation (Table 3
and Supplementary Table 2). g-Glutamyl hydrolase expression
was lower, whereas ECGF1 was higher in tumour with these
CIMPþ features. The analyses showed that low expression of GGH
was consistently associated with CIMPþ and CIMPþ-related
features (Figure 1). The high expression levels of RRM2 and ECGF1
also showed strong associations with CIMPþ and CIMPþ-related
features, respectively.
Finally, mRNA expression was compared to the concentrations
of the folate intermediates CH2FH4 and FH4 in these CRC tissues
(Table 4). None of the genes examined showed significant
correlation with the concentrations of these intermediates,
although high RFC1 expression was significantly correlated with
low concentrations of FH4 (Spearman’s r¼ 0.205, P¼0.046).
Trends for negative correlation between GGH expression and
CH2FH4 and FH4 concentrations were observed (Spearman’s
r¼ 0.200, P¼0.053 and Spearman’s r¼ 0.180, P¼0.083,
respectively). The above exploratory analyses suggest that low
GGH mRNA expression is a candidate CIMPþ molecular
signature, possibly through its involvement in folate metabolism.
Validation of GGH downregulation in CIMPþ CRC
A validation study was conducted using 150 primary CRC samples
from a Japanese cohort of patients. g-Glutamyl hydrolase, ECGF1
Table 2 Associations between mRNA expression and CIMP status in
CRC from an Australian cohort
mRNA expression level
Gene symbol CIMP+ CIMP  P-value
CDA 3.44 (1.79–5.05) 2.08 (0.92–4.28) 0.131
DCK 2.78 (2.57–3.22) 2.49 (1.67–3.00) 0.025
DCTD 4.21 (3.52–5.21) 4.04 (3.00–5.24) 0.403
DHFR 4.67 (3.52–5.37) 3.72 (2.84–5.38) 0.129
DPYD 0.48 (0.32–0.76) 0.32 (0.24–0.48) 0.025
DUT 123.8 (53.6–196.8) 116.2 (68.1–166.2) 0.828
ECGF1 4.76 (3.16–7.08) 2.71 (1.93–4.01) 0.001
FOLR1 0.00 (0.00–0.07) 0.10 (0.00–0.43) 0.060
FPGS 0.77 (0.56–0.95) 0.70 (0.52–0.85) 0.458
GGH 1.97 (1.04–3.06) 3.31 (1.98–5.69) 0.013
MTHFD1 4.46 (3.76–5.11) 3.84 (2.90–5.08) 0.197
MTHFR 1.20 (0.97–1.40) 0.91 (0.65–1.34) 0.044
RFC1 2.97 (2.29–4.30) 2.91 (1.99–3.92) 0.923
RRM1 1.02 (0.84–1.29) 0.96 (0.65–1.27) 0.265
RRM2 6.96 (4.60–7.70) 3.51 (2.27–6.03) 0.004
TYMS 3.32 (2.48–5.81) 2.99 (1.91–4.24) 0.099
UMPS 1.17 (1.07–1.40) 1.29 (0.96–1.73) 0.660
CIMP¼CpG island methylator phenotype; CRC¼colorectal cancer. mRNA
expression levels are shown as median (25th to 75th percentiles). The
Mann–Whitney U-test was used for statistical analysis.
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Figure 1 g-Glutamyl hydrolase mRNA expression according to the
CIMP status, tumour site, TILs and BRAF mutation status in an Australian
CRC cohort was shown by boxplot. The level of GGH mRNA expression
was significantly different between all dichotomised variables
(Mann–Whitney U-test; CIMP, P¼0.013; tumour site, P¼0.021; TILs,
P¼0.001; BRAF mutation, P¼0.002).
Table 3 Associations between mRNA expression and clinicopathologi-
cal and molecular features in CRC from an Australian cohort
Tumour site TILs BRAF mutation
Gene symbol Proximal Distal Present Absent Present Absent
CDA 2.08 2.42 2.06 2.21 3.81 2.12
DCK 2.55 2.59 2.90 2.53* 2.70 2.54
DCTD 3.97 4.28 4.39 4.07 4.01 4.08
DHFR 3.74 4.39 4.52 3.78 4.75 3.90
DPYD 0.36 0.30 0.62 0.32* 0.59 0.32
DUT 123.2 117.2 166.3 112.7 126.3 114.6
ECGF1 3.44 2.50* 5.29 2.85** 6.73 2.96**
FOLR1 0.00 0.16** 0.15 0.08 0.00 0.08
FPGS 0.67 0.73 0.76 0.70 0.73 0.70
GGH 2.44 3.91* 1.38 3.35** 1.38 3.33**
MTHFD1 3.94 4.06 4.15 3.98 4.68 3.87
MTHFR 1.12 0.85 1.28 0.94 1.32 0.94*
RFC1 2.68 3.16* 2.70 3.00 2.70 3.02
RRM1 0.94 0.99 0.99 0.95 1.07 0.96
RRM2 4.36 4.28 5.33 3.91 7.01 3.91*
TYMS 3.35 2.69 4.74 2.64** 4.48 2.99*
UMPS 1.14 1.36* 1.13 1.29 1.13 1.30
CRC¼colorectal cancer; TILs¼tumour-infiltrating lymphocytes. Median mRNA
expression levels are shown. The Mann–Whitney U-test was used for statistical
analysis. *Po0.05; **Po0.01. Data presented with median (25th to 75th percentiles)
and P-value are available in Supplementary Table 2.
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sand RRM2 were selected as candidates for further study because
the expression of these genes was consistently associated with
CIMPþ and/or CIMPþ-related features in the Australian CRC
series. Only 14 out of 150 (9.3%) of the Japanese CRC samples were
found to be CIMPþ compared to 15.8% of the Australian tumours
(P¼0.11 in w
2 test). A random selection of CIMP  CRC (n¼79)
and all 14 CIMPþ CRC samples from the Japanese cohort were
subjected to RT-PCR analysis of GGH, ECGF1 and RRM2
expression. The results confirmed the previous result that GGH
mRNA expression was significantly lower in CIMPþ CRC samples
from a separate tumour series (P¼0.0012, Figure 2). No significant
associations were observed between CIMPþ and either ECGF1 or
RRM2 mRNA expression.
To further examine whether the mRNA level reflects GGH
protein expression, selected paraffin tissues of Japanese CRC were
immunostained using polyclonal antibody to human GGH. g-
Glutamyl hydrolase protein was not detectable or was weakly
expressed in four samples with low mRNA levels (0.01, 0.06, 0.28
and 0.32), whereas much stronger expression was observed in five
samples with high mRNA levels (3.25, 3.50, 3.73, 6.33 and 8.29).
Representative cases are shown in Figure 3. The results indicate an
association between levels of GGH mRNA and its protein
expression.
Table 4 Associations between mRNA expression level and the
concentration of folate intermediates in CRC from an Australian cohort
CH2FH4 FH4
Gene symbol Spearman’s q P-value Spearman’s q P-value
CDA 0.205 0.063 0.154 0.163
DCK 0.058 0.583 0.056 0.599
DCTD  0.042 0.684 0.024 0.817
DHFR  0.081 0.448  0.145 0.174
DPYD 0.020 0.845 0.010 0.924
DUT  0.022 0.834  0.022 0.834
ECGF1 0.062 0.559 0.043 0.686
FOLR1  0.136 0.190  0.073 0.481
FPGS  0.025 0.807 0.023 0.822
GGH  0.200 0.053  0.180 0.083
MTHFD1  0.014 0.856  0.033 0.752
MTHFR  0.028 0.784 0.037 0.720
RFC1  0.159 0.123  0.205 0.046
RRM1 0.039 0.707 0.006 0.952
RRM2 0.107 0.303 0.046 0.661
TYMS 0.076 0.471  0.018 0.864
UMPS  0.121 0.246  0.050 0.630
CRC¼colorectal cancer. Spearman’s rank correlation test was used for analyses.
Spearman’s r and P-value are presented for each analysis of correlations.
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Figure 2 g-Glutamyl hydrolase mRNA expression according to the
CIMP status in a Japanese CRC cohort used for validation was shown by
boxplot. Lower GGH expression in CIMPþ compared to CIMP  CRC
was confirmed (Mann–Whitney U-test; P¼0.0012).
5209 2426
4040 616
100 m 100 m
100 m 100 m
Figure 3 Immunohistochemical staining of GGH in CRC tissues. g-Glutamyl hydrolase protein was not detectable in tumour cells in case Nos. 5209 and
2426, in which the GGH mRNA levels were 0.01 and 0.06, respectively. Expression of GGH was observed in tumour cells in case Nos. 4040 and 616, in
which the GGH mRNA levels were 3.73 and 8.29, respectively.
GGH expression and DNA methylation
K Kawakami et al
1558
British Journal of Cancer (2008) 98(9), 1555–1561 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sGGH promoter methylation is not a cause of GGH
downregulation in CIMPþ CRC
A recent study in leukaemia found that hypermethylation of the GGH
promoter was associated with silencing of GGH gene expression
(Cheng et al, 2006). The above exploratory analyses showing that
CIMPþ CRC samples have low GGH mRNA expression levels also
raise this possibility. Methylation of the GGH promoter was therefore
analysed in 18 CIMPþ tumours and in 20 randomly selected
CIMP  tumours from the Australian CRC cohort. Only one CIMPþ
tumour (5.6%) showed hypermethylation of the GGH promoter
(Figure 4), indicating that it does not play a major role in
downregulating the mRNA expression of this gene in CRC.
DISCUSSION
In this study, we explored the possibility that genes involved in
folate and nucleotide metabolism have a distinct mRNA expression
signature in CIMPþ CRC. Although no clear expression pattern
was found for the 17 genes analysed, low GGH expression was
observed in two independent series of CIMPþ CRC and could
therefore play a role in the development of this phenotype. In the
Australian CRC cohort, the mRNA expression levels for GGH and
RRM2 were shown by univariate and multivariate analyses to be
significantly associated with CIMPþ CRC. In addition, the mRNA
expression of GGH and ECGF1 was associated with characteristic
clinicopathological and molecular features of CIMPþ, including
proximal tumour site, TILs and BRAF mutation. Moreover, the
concentrations of two folate intermediates, CH2FH4 and FH4,
showed trends for association with GGH mRNA expression. As
might be predicted from the function of GGH in hydrolysing
glutamated folates and allowing escape from the cell (Figure 5), low
GGH expression was associated with higher folate concentrations.
Overall, the results of the exploratory study on the Australian
CRC cohort provided evidence that low expression of GGH mRNA
was associated with CIMPþ and with CIMPþ-related features.
This led us to conduct a further study using an independent cohort
of primary CRC from Japan and in which we confirmed the
relationship between low GGH mRNA expression and CIMPþ
status. The frequency of CIMPþ was lower among Japanese CRC
(9.3%) than that among Australian CRC (15.8%). Although this
difference did not reach statistical significance, it suggests that
dietary, environmental and genetic differences between these two
populations could influence the frequency of the CIMPþ
subgroup as a proportion of total CRC. Nevertheless, low
expression of GGH mRNA was a consistent finding in both
CIMPþ cohorts. Although a recommended panel of markers was
used here to define CIMPþ (Weisenberger et al, 2006), the GGH/
CIMPþ association was also found using a different CpG island
panel comprising of MLH1, p16 (INK4A), TIMP3 and p14 (ARF)
(data not shown).
The present results suggest that low GGH mRNA expression may
play a role in the development and/or progression of CIMPþ CRC.
A possible explanation for this is the role played by GGH in
regulating intracellular folate levels (Figure 5). Monoglutamyl folate
is transported into mammalian cells mainly by FOLR1 and RFC1
(Matherly and Goldman, 2003). Intracellular monoglutamyl folate is
converted to the polyglutamate form by FPGS (Qi et al, 1999),
whereas the polyglutamate chains are removed by GGH (Schneider
and Ryan, 2006). Polyglutamate forms of folate are more strongly
retained within the cell and are a better substrate for intracellular
folate-dependent enzymes than the monoglutamate form. Therefore,
low GGH expression would be expected to lead to a higher
concentration of polyglutamated folate because of better retention
in the cell. In agreement with this, we observed trends for an inverse
correlation between GGH expression and the concentrations of folate
intermediates CH2FH4 and FH4 (Table 4). FOLR1 and FPGS mRNA
expression were not associated with the concentrations of these
folate intermediates; however, the increased expression of RFC1 was
significantly correlated with low concentrations of FH4. These results
suggest that GGH expression plays a role in regulating the
intracellular folate level in CRC tissues, although other factors such
as RFC1 expression are also likely to be involved.
We previously reported that frequent CpG promoter hyper-
methylation was associated with high folate levels in CRC
(Kawakami et al, 2003). A recent study also found that the level
of p16 (INK4A) promoter methylation in the normal colonic
mucosa of older mice increased following folate supplementation
(Keyes et al, 2007). Together, the above results suggest that low
GGH expression may be linked to increased promoter methylation
UM UM UM UM UMUM UM UM UM UM
UM UM UM UM UM UM UM UM UM UM
UC MC CIMP+
CIMP– WiDr
Figure 4 Methylation-specific PCR analysis of the GGH promoter.
Promoter methylation of GGH was analysed using unmethylated DNA-
specific primer sets (U) and methylated DNA-specific primer sets (M).
Representative results using 18 samples of CIMPþ and 20 randomly
selected samples of CIMP  tumours are shown. Only one sample, a
CIMPþ tumour, showed GGH promoter hypermethylation. Sperm DNA
and fully methylated sperm DNA produced with SssI methylase were used
for unmethylated control (UC) and methylated control (MC), respectively.
DNA from the colon cancer cell line WiDr was also used as a positive
control.
Membrane
GGH FPGS
One-carbon transfer reactions
: RFC1
: FOLR1
: Folate
: Glutamate
Figure 5 Simplified representation of folate transport and polyglutamy-
lation reactions within the cell. RFC1 is ubiquitously expressed in epithelial
cells and plays a role as a major transport system for folates. FOLR1 is
anchored to cell membranes and transports folates via an endocytotic
process. Intracellular monoglutamyl folate is converted to the polygluta-
mate form by FPGS, whereas the polyglutamate chains are removed by
GGH.
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sin CIMPþ tumours by causing elevation of the folate concentra-
tion. An alternate explanation involving transcriptional silencing
of GGH by promoter methylation was excluded by the finding that
only 5.6% of CIMPþ tumours showed GGH hypermethylation
(Figure 4). It is unknown whether low GGH expression and its link
with high tissue folate concentrations play a causal or even
supportive role in the development of CIMPþ CRC. Further
studies are required in which GGH expression, folate status and
CpG island methylation are evaluated in normal colonic tissue as
well as in the proposed precursor lesion for CIMPþ, the so-called
serrated adenoma or hyperplastic polyp (Jass, 2006). The
mechanism(s) by which GGH expression is regulated in both
normal and malignant colorectal tissue also warrants further
investigation. Apart from two studies that found GGH expression
was increased in CRC compared to adjacent normal colonic
mucosa (Odin et al, 2003; Kidd et al, 2005), no other work has been
published in this area.
In addition to possible implications for the aetiology of CIMPþ CRC,
the current findings are also relevant for the response of CRC to
inhibitors of dihydrofolate reductase and thymidylate synthase (TS),
both of which are key enzymes in nucleotide synthesis. The growth
inhibitory effect of anti-folates such as methotrexate (MTX) and
raltitrexed depends upon the polyglutamylation state of these agents
(Barnes et al, 1999). Methotrexate is transported into cells using the same
mechanism as that for folates and is also better retained following
polyglutamylation. High GGH activity has been associated with the
resistance of tumour cell lines to MTX via shortening of polyglutamate
chains and consequently a lower intracellular drug concentration and
less inhibition of dihydrofolate reductase and TS (Rhee et al, 1993;
Barnes et al, 1999). Raltitrexed, a specific inhibitor of TS, is also
polyglutamylated and its antitumour activity correlates with the amount
of polyglutamylated drug inside the cells (Takemura et al, 1996). The
importance of polyglutamylation in the antitumour activity suggests that
CIMPþ CRC might have higher sensitivity to these anti-folates because
of low GGH expression in this subtype of CRC. Neither MTX nor
raltitrexed is widely used in chemotherapy for CRC. However, these anti-
folates might be of clinical use for tailored chemotherapy.
In contrast to above-mentioned anti-folates, 5-fluorouracil (5-
FU) and leucovorin have been key drugs for the chemotherapy of
CRC. 5-Fluorouracil is thought to exert its major cytotoxic activity
by inhibiting TS. It does this by forming a stable ternary complex
between 5,10-methylenetetrahydrofolate, TS and fluoro-dUMP, the
metabolite of 5-FU (Longley et al, 2003). Leucovorin, also known
as folinic acid, increases the activity of 5-FU by raising the
intracellular levels of 5,10-methylenetetrahydrofolate and thereby
prolonging the inhibition of TS. 5,10-Methylenetetrahydrofolate is
also better retained following polyglutamylation (Radparvar et al,
1989), and this is critical for the antitumour activity of 5-FU even
when this folate intermediate is present at relatively high
concentrations (Romanini et al, 1991). Therefore, supplementation
of 5-FU with leucovorin may be more effective in CIMPþ
compared to CIMP  CRC because the low GGH levels would better
allow the retention and modulatory action of 5,10-methylenete-
trahydrofolate. An earlier study did indeed find that adjuvant
treatment with 5-FU/leucovorin conferred more benefit to CIMPþ
tumours in stage III CRC (van Rijnsoever et al, 2003). Two more
recent studies reported that CIMPþ CRC was associated with
poor survival in advanced CRC treated with 5-FU-based
chemotherapy (Ogino et al, 2007; Shen et al, 2007). This may,
however, be a reflection of the prognostic rather than predictive
value of CIMPþ. Moreover, the regimens used in the two studies
of advanced CRC included not only 5-FU alone but also in
combination with other chemotheraputic agents such as IFNa-2a
and irinotecan. Further prospective studies are needed to test
whether CIMPþ is a predictive marker for response to 5-FU/
leucovorin in CRC. These may allow chemotherapy regimens to be
tailored according to the CIMPþ status, leading to more effective
cancer treatment.
The present study investigated 17 genes involved in folate and
nucleotide metabolism. Low expression of GGH was one of the
features associated with CIMPþ CRC; however, it was not a specific
marker for this phenotype because many CIMP  tumours also
showed low expression of this gene. The aberrant promoter
methylation observed in CIMPþ CRC is likely to be a multistep
phenomenon that involves many factors in addition to folate
metabolism and could include, for example, the expression levels
of methyltransferases and histone deacetylase. Some of these factors
may be revealed by array-based transcriptome analysis of CIMPþ
and CIMP  CRC tissues. Although no study to date has addressed
this issue, a few reports have described the mRNA expression profile
of the closely associated MSIþ phenotype in CRC (Banerjea et al,
2004; di Pietro et al, 2005; Lanza et al, 2007). Interestingly, each of
these studies showed that GGH mRNA expression was lower in
MSIþ compared to MSI  CRC. Because of the strong concordance
between MSIþ and CIMPþ in population-based CRC cohorts
(Hawkins et al, 2002; van Rijnsoever et al, 2002; Samowitz et al,2 0 0 5 ;
Ogino et al, 2006; Weisenberger et al, 2006), the results from these
independent, array-based studies confirm the current results
obtained using RT-PCR and two separate CIMPþ CRC series.
Together, the studies provide strong evidences of low GGH
expression in MSIþ and/or CIMPþ CRC. The three array-based
studies did not show consistent association between expression of
the other genes analysed in current study with MSI status. However,
two of them (Banerjea et al, 2004; di Pietro et al,2 0 0 5 )d e m o n s t r a t e d
higher expression of TYMS in MSIþ compared to MSI  CRC. Our
result on TYMS expression between CIMPþ and CIMP  CRC did
not support this association (P¼0.099, Table 2). TYMS might
differently express in MSIþ compared to CIMPþ CRC, requiring
further study to establish molecular difference between MSIþ and
CIMPþ CRC.
In conclusion, the present study is the first to investigate the
expression of genes involved in folate and nucleotide metabolism in
relation to CIMPþ CRC. This tumour phenotype is associated with
low expression of GGH, suggesting involvement of the folate pathway
in its development and/or growth. Further studies of folate
metabolism in CIMPþ CRC, premalignant precursors and normal
colonic mucosa may help to elucidate the aetiology of these tumours.
A better understanding of the role of folate metabolism in DNA
methylation may also lead to tailored chemotherapy that employs
anti-folates, 5-FU/leucovorin and the use of CIMPþ markers.
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